La Jolla Pharmaceutical (NASDAQ:LJPC) major shareholder Life Sciences Maste Perceptive sold 2,060,235 shares of La Jolla Pharmaceutical stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $5.69, for a total transaction of $11,722,737.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
NASDAQ LJPC opened at $6.10 on Friday. La Jolla Pharmaceutical has a 12-month low of $5.01 and a 12-month high of $41.36. The firm has a market capitalization of $275.98 million, a price-to-earnings ratio of -1.13 and a beta of 1.72.
La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.01) by $0.08. The firm had revenue of $3.47 million during the quarter, compared to analysts’ expectations of $3.38 million. As a group, sell-side analysts anticipate that La Jolla Pharmaceutical will post -7.97 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC grew its holdings in shares of La Jolla Pharmaceutical by 7.5% during the third quarter. FMR LLC now owns 3,933,641 shares of the biopharmaceutical company’s stock valued at $79,184,000 after buying an additional 275,957 shares during the last quarter. Jennison Associates LLC lifted its position in La Jolla Pharmaceutical by 2.8% during the third quarter. Jennison Associates LLC now owns 3,279,272 shares of the biopharmaceutical company’s stock valued at $66,012,000 after purchasing an additional 90,739 shares during the period. Scopia Capital Management LP lifted its position in La Jolla Pharmaceutical by 0.3% during the third quarter. Scopia Capital Management LP now owns 2,590,212 shares of the biopharmaceutical company’s stock valued at $52,141,000 after purchasing an additional 7,042 shares during the period. BlackRock Inc. lifted its position in La Jolla Pharmaceutical by 1.8% during the third quarter. BlackRock Inc. now owns 1,480,004 shares of the biopharmaceutical company’s stock valued at $29,791,000 after purchasing an additional 25,877 shares during the period. Finally, Pictet Asset Management Ltd. lifted its position in La Jolla Pharmaceutical by 12.9% during the third quarter. Pictet Asset Management Ltd. now owns 1,066,021 shares of the biopharmaceutical company’s stock valued at $21,459,000 after purchasing an additional 121,594 shares during the period.
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.
Read More: Beta
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.